MRNA Jun 2025 55.000 call
| Previous close | 14.60 |
| Open | 14.00 |
| Bid | 13.50 |
| Ask | 13.80 |
| Strike | 55.00 |
| Expiry date | 2025-06-20 |
| Day's range | 14.00 - 14.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 203 |
Investor's Business DailyIs Moderna Stock A Sell After The Company Slashed Its R&D Budget?
Moderna stock tumbled after the company issued a light 2025 sales outlook and cut its 2027 R&D budget. Is MRNA stock a sell?
BloombergCovid-Shot Maker Goes Bankrupt After Trailing Pfizer, Moderna
(Bloomberg) -- Gritstone Bio Inc., a vaccine developer that once touted its ability to make a next-generation Covid-19 shot, filed for Chapter 11 bankruptcy in Delaware Thursday. Most Read from BloombergSan Francisco to Shut 9% of Public Schools Amid Budget WoesThe Cablebus Transformed Commutes in Mexico City’s Populous OutskirtsChicago’s $1 Billion Budget Hole Exacerbated by School TurmoilUrban Heat Stress Is Another Disparity in the World’s Most Unequal NationShould Evictions Be Banned After H
ZacksGSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.
